Papillary renal cell carcinoma

A Transformational Year: ImaginAb expands Pipeline to include Radiopharmaceutical Therapies, enters Multiple Partnerships, and Drives Forward Development of Investigational CD8 ImmunoPET Agent

Retrieved on: 
Tuesday, October 4, 2022
CD8, Society for Immunotherapy of Cancer, RPT, Prognosis, GMA, Society, GMP, AstraZeneca, Boehringer Ingelheim, Medication, Technology, BOT, Research, IND, Biologics license application, Memorial Sloan Kettering Cancer Center, Immunotherapy, Cave rescue, MSKCC, Atezolizumab, Patient, Papillary renal cell carcinoma, COVID-19, Phase II, Roche, CRO, PET, University of California, Davis, Partnership, BLA, Pfizer, Inclusion body myositis, SITC, United Kingdom, IPredict, Radiopharmaceutical, University, IBM, Melanoma, Data analysis, CMO, Fine chemical, Pharmaceutical industry, Medical imaging, Biotechnology

ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.

Key Points: 
  • ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.
  • In August 2021, ImaginAb completed its Phase I IBM study showing utility of CD8 ImmunoPET to detect disease pathology in Inclusion Body Myositis (IBM) patients.
  • ImaginAb formally launched its Phase IIb 'iPREDICT' study to measure CD8 ImmunoPET imaging predictivity and prognosis, building on the data from its promising Phase IIa 'BOT' study.
  • These GMA agreements include:
    PharmaLogic, the fastest growing radiopharmaceutical manufacturer in North America, to manufacture and distribute CD8 ImmunoPET for ImaginAb.

A Transformational Year: ImaginAb expands Pipeline to include Radiopharmaceutical Therapies, enters Multiple Partnerships, and Drives Forward Development of Investigational CD8 ImmunoPET Agent

Retrieved on: 
Tuesday, October 4, 2022
CD8, Society for Immunotherapy of Cancer, RPT, Prognosis, GMA, Society, GMP, AstraZeneca, Boehringer Ingelheim, Medication, Technology, BOT, Research, IND, Biologics license application, Memorial Sloan Kettering Cancer Center, Immunotherapy, Cave rescue, MSKCC, Atezolizumab, Patient, Papillary renal cell carcinoma, COVID-19, Phase II, Roche, CRO, PET, University of California, Davis, Partnership, BLA, Pfizer, Inclusion body myositis, SITC, United Kingdom, IPredict, Radiopharmaceutical, University, IBM, Melanoma, Data analysis, CMO, Fine chemical, Pharmaceutical industry, Medical imaging, Biotechnology

ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.

Key Points: 
  • ImaginAb continues the clinical development of CD8 ImmunoPET with a target to file a Biologics License Application (BLA) submission in the next two years.
  • In August 2021, ImaginAb completed its Phase I IBM study showing utility of CD8 ImmunoPET to detect disease pathology in Inclusion Body Myositis (IBM) patients.
  • ImaginAb formally launched its Phase IIb 'iPREDICT' study to measure CD8 ImmunoPET imaging predictivity and prognosis, building on the data from its promising Phase IIa 'BOT' study.
  • These GMA agreements include:
    PharmaLogic, the fastest growing radiopharmaceutical manufacturer in North America, to manufacture and distribute CD8 ImmunoPET for ImaginAb.

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

Retrieved on: 
Wednesday, November 24, 2021
Man, NSCLC, Lung, Pemetrexed, Disease, TKI, Woman, Recurrence, Papillary renal cell carcinoma, Kidney, Pharmacokinetics, PFS, New Drug Application, Cisplatin, Mutation, Neoplasm, GLOBE, Colorectal cancer, National Medical Products Administration, Lung cancer, AIM, LinkedIn, Renal medullary carcinoma, TTR, PD-L1, Private Securities Litigation Reform Act, Cancer, Carboplatin, LAURA, HCM, HIV disease progression rates, Patient, AstraZeneca, Adenocarcinoma, DCR, Squamous cell carcinoma, Conference, Forward-looking statement, Gene amplification, Therapy, U.S. Securities and Exchange Commission, Growth, Sunitinib, Safety, MET, GC, Hong Kong Stock Exchange, Program, Dor, COVID-19, Hereditary diffuse gastric cancer, GEJ, ORR, NMPA, ASCO, Pharmaceutical industry

HONG KONG and FLORHAM PARK, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/​AIM:​HCM; HKEX:​13) and AstraZeneca PLC (“AstraZeneca”) (LSE/​STO/​Nasdaq:​AZN) have initiated SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) TKI, TAGRISSO® (osimertinib). The first patient received their first dose on November 22, 2021.

Key Points: 
  • The Phase III trial is a multi-center, open-label, randomized, controlled study in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) with MET amplification after disease progression on EGFR inhibitor therapy.
  • It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers, as a single treatment and in combination with other medicines.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize savolitinib.
  • Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China.

HER2 Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 21, 2021
Health, Pharmaceutical, Woman, Papillary renal cell carcinoma, Squamous cell carcinoma, Breast cancer, Growth, Cancer, Adenocarcinoma, Organization, History, Patient, World Health Organization, World, Novartis, Pfizer, Risk, Boehringer Ingelheim, Mylan, Pressure, Trastuzumab, COVID-19, American Cancer Society, WHO, HER2, Population, Incidence, Fine chemical, Pharmaceutical industry, Birth control

The "HER2 Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HER2 Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The HER2 inhibitors market consists of sales of HER2 inhibitors and related services by entities (organizations, sole traders, and partnerships) that manufacture HER2 inhibitors.
  • Human epidermal growth factor receptor (HER2) inhibitors slow down or stop cell growth thus reducing the risk for cancer growth.
  • Therefore, the high cost of HER2 inhibitors is expected to hinder the growth of the HER2 inhibitors market.

HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Retrieved on: 
Wednesday, September 8, 2021

The Phase III trial is a blinded, randomized, controlled study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression.

Key Points: 
  • The Phase III trial is a blinded, randomized, controlled study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression.
  • The study will evaluate the efficacy and safety of TAGRISSO in combination with ORPATHYS comparing to TAGRISSO alone, a standard-of-care treatment option for these patients.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize savolitinib.
  • Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China.

Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU

Retrieved on: 
Saturday, February 13, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Bristol-Myers Squibb, Clinical medicine, Drugs, Medicine, Antineoplastic drugs, Breakthrough therapy, Ipilimumab, Renal cell carcinoma, Sunitinib, Nivolumab, Papillary renal cell carcinoma, the SWOG S1500 Clinical Trial, Papillary Renal Cell Carcinoma, CABOMETYX® (cabozantinib), Exelixis

Its gratifying to see these positive results of the PAPMET trial, which may help physicians choose an appropriate therapy for their patients with advanced papillary renal cell carcinoma.

Key Points: 
  • Its gratifying to see these positive results of the PAPMET trial, which may help physicians choose an appropriate therapy for their patients with advanced papillary renal cell carcinoma.
  • The discontinuation rate of study medications due to treatment-related adverse events was 24% for sunitinib and 23% for CABOMETYX.
  • The most common grade 3 or 4 adverse events with CABOMETYX were hypertension (32%), hand-foot syndrome (20%) and fatigue (13%).
  • Prior therapy was received by 10 patients (7%), and the most common prior therapy was the combination of nivolumab with ipilimumab (4 patients).